Literature DB >> 6439744

Studies of Factors V and VIII:C in an animal model of disseminated intravascular coagulation.

A R Giles, M E Nesheim, K G Mann.   

Abstract

An experimental animal model of disseminated intravascular coagulation (DIC) induced by the co-infusion of coagulant-active phospholipid and activated Factor X (Factor Xa) is described. The infusion of Factor Xa at a dose of 6.6 X 10(-12) mol/kg with phosphatidylcholine/phosphatidylserine (PCPS) lipid vesicles at a dose of 4.0 X 10(-8) mol/kg was associated with significant falls in the levels of fibrinogen and Factors V and VIII, and a bleeding diathesis developed. Assays of Factors V and VIII were performed by a one-stage prothrombin time and activated partial thrombin time system, respectively. In additional experiments, the effect of the same dose combination of Factor Xa/PCPS on Factor V kinetics was studied by preinfusing 125I-labeled Factor V. After Factor Xa/PCPS infusion, Factors VIII and V were reduced at 2 min by 90 and 50% of the preinfusion levels, respectively, and at 1 h by 80 and 75%, respectively. During the same period, there was little change in the total circulating radioactivity. Autoradiography indicated small but detectable levels of circulating proteolytic products of Factor V that comigrated with peptides obtained by the incubation of Factor V with Factor Xa and activated protein C. The majority of radioactivity remained associated with the intact single-chain precursor Factor V. These observations suggested maintenance of the precursor pool after the onset of DIC. This was confirmed by performing two-stage assays of Factors V and VIII, whereby each was completely converted to the active cofactor, i.e., Va and VIII:Ca, by preincubation of the test sample with thrombin before assaying in a one-stage system as before. The Factor V levels assayed by the two-stage procedure did not change appreciably over 1 h. The Factor VIII levels fell but corrected within 1 h at a time when the level measured by a one-stage assay remained depressed. These results indicate that in the dog, infusion of Factor Xa/PCPS induces changes characteristic of DIC, and this is associated with the appearance of Factor V peptides characteristic of the expression of Factor Xa and activated protein C-like activities. The differences noted between the one-stage and two-stage assays suggest that the one-stage assay is measuring the activated fraction of each cofactor and not the total level of the available precursor for each activated species. The results suggest a close correlation between the activated fraction of both cofactors and the hemostatic abnormality that occurs in DIC.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6439744      PMCID: PMC425414          DOI: 10.1172/JCI111648

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  23 in total

1.  Anticoagulant properties of bovine plasma protein C following activation by thrombin.

Authors:  W Kisiel; W M Canfield; L H Ericsson; E W Davie
Journal:  Biochemistry       Date:  1977-12-27       Impact factor: 3.162

2.  Proteolytic alterations of factor Va bound to platelets.

Authors:  P B Tracy; M E Nesheim; K G Mann
Journal:  J Biol Chem       Date:  1983-01-10       Impact factor: 5.157

Review 3.  Factor V.

Authors:  M E Nesheim; J A Katzmann; P B Tracy; K G Mann
Journal:  Methods Enzymol       Date:  1981       Impact factor: 1.600

4.  The inhibition of blood coagulation by activated Protein C through the selective inactivation of activated Factor V.

Authors:  F J Walker; P W Sexton; C T Esmon
Journal:  Biochim Biophys Acta       Date:  1979-12-07

5.  Isolation and characterization of single chain bovine factor V.

Authors:  M E Nesheim; K H Myrmel; L Hibbard; K G Mann
Journal:  J Biol Chem       Date:  1979-01-25       Impact factor: 5.157

6.  Activation of protein C in vivo.

Authors:  P C Comp; R M Jacocks; G L Ferrell; C T Esmon
Journal:  J Clin Invest       Date:  1982-07       Impact factor: 14.808

7.  A lysine-absorbable plasminogen activator is elevated in conditions associated with increased fibrinolytic activity.

Authors:  P C Comp; R M Jacocks; C Rubenstein; R Radcliffe
Journal:  J Lab Clin Med       Date:  1981-05

8.  A canine model of hemophilic (factor VIII:C deficiency) bleeding.

Authors:  A R Giles; S Tinlin; R Greenwood
Journal:  Blood       Date:  1982-09       Impact factor: 22.113

9.  The coagulant-active phospholipid content is a major determinant of in vivo thrombogenicity of prothrombin complex (Factor IX) concentrates in rabbits.

Authors:  A R Giles; M E Nesheim; H Hoogendoorn; P B Tracy; K G Mann
Journal:  Blood       Date:  1982-02       Impact factor: 22.113

10.  Generation of fibrinolytic activity by infusion of activated protein C into dogs.

Authors:  P C Comp; C T Esmon
Journal:  J Clin Invest       Date:  1981-11       Impact factor: 14.808

View more
  9 in total

Review 1.  Disseminated intravascular coagulation: old disease, new hope.

Authors:  Cheng Hock Toh; Michael Dennis
Journal:  BMJ       Date:  2003-10-25

2.  Hemostatic agents of broad applicability produced by selective tuning of factor Xa zymogenicity.

Authors:  Lacramioara Ivanciu; Rodney M Camire
Journal:  Blood       Date:  2015-04-20       Impact factor: 22.113

3.  Zymogen-like factor Xa variants restore thrombin generation and effectively bypass the intrinsic pathway in vitro.

Authors:  Matthew W Bunce; Raffaella Toso; Rodney M Camire
Journal:  Blood       Date:  2010-09-23       Impact factor: 22.113

Review 4.  The Effect of Heparin and Its Preparations on Disseminated Intravascular Coagulation Mortality and Hospitalization: A Systematic Review.

Authors:  Navid Omidkhoda; Farshad Abedi; Vahid Ghavami; Hossein Rahimi; Sara Samadi; Omid Arasteh; Amir Hooshang Mohammadpour
Journal:  Int J Clin Pract       Date:  2022-07-09       Impact factor: 3.149

5.  Antithrombotic effects of thrombin-induced activation of endogenous protein C in primates.

Authors:  S R Hanson; J H Griffin; L A Harker; A B Kelly; C T Esmon; A Gruber
Journal:  J Clin Invest       Date:  1993-10       Impact factor: 14.808

6.  Factor VIII-bypassing activity of bovine tissue factor using the canine hemophilic model.

Authors:  D P O'Brien; A R Giles; K M Tate; G A Vehar
Journal:  J Clin Invest       Date:  1988-07       Impact factor: 14.808

7.  A zymogen-like factor Xa variant corrects the coagulation defect in hemophilia.

Authors:  Lacramioara Ivanciu; Raffaella Toso; Paris Margaritis; Giulia Pavani; Haein Kim; Alexander Schlachterman; Jian-Hua Liu; Valerie Clerin; Debra D Pittman; Rosalind Rose-Miranda; Kathleen M Shields; David V Erbe; James F Tobin; Valder R Arruda; Rodney M Camire
Journal:  Nat Biotechnol       Date:  2011-10-23       Impact factor: 54.908

Review 8.  Local hemostasis, immunothrombosis, and systemic disseminated intravascular coagulation in trauma and traumatic shock.

Authors:  Satoshi Gando; Yasuhiro Otomo
Journal:  Crit Care       Date:  2015-02-23       Impact factor: 9.097

9.  Disseminated Intravascular Coagulation: An Update on Pathogenesis, Diagnosis, and Therapeutic Strategies.

Authors:  Chrysoula Papageorgiou; Georges Jourdi; Eusebe Adjambri; Amanda Walborn; Priya Patel; Jawed Fareed; Ismail Elalamy; Debra Hoppensteadt; Grigoris T Gerotziafas
Journal:  Clin Appl Thromb Hemost       Date:  2018-10-08       Impact factor: 2.389

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.